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1Chapter
Resolving the Debate on RSV 
Prophylaxis in Late Preterm 
Infants
Bosco Paes, Barry Rodgers-Gray and Xavier Carbonell-Estrany
Abstract
There is still active debate in the scientific literature about the importance of 
providing respiratory syncytial virus (RSV) prophylaxis to late preterm infants 
born at 33–35 weeks’ gestational age (wGA). The American Academy of Pediatrics 
and the Canadian Paediatric Society position statements only advocate for RSV 
prophylaxis for infants <30 wGA. Several publications prove the contrary, report-
ing substantial morbidity and even mortality in older GA infants, following RSV 
infection. Consequently, other Societies, such as from Spain and Italy, have differ-
ent criteria, and include as candidates 30–32 wGA infants and 33–35 wGA infants 
with risk factors for severe RSV disease. This chapter will systematically examine 
the current evidence for RSV prophylaxis in both early and late preterm infants 
29–35 wGA and the cost-effectiveness of this strategy with the use of risk scoring 
tools. The authors will attempt to reconcile the misconception that late preterm 
infants do not merit RSV prophylaxis and hopefully resolve the long-standing 
debate that currently exists in many countries worldwide.
Keywords: respiratory syncytial virus, palivizumab, prematurity, cost effectiveness, 
prevention, risk scoring tools
1. Introduction
Respiratory syncytial virus (RSV) infection is a common cause of lower respira-
tory tract infection (LRTI) in young children and is associated with a high global 
burden of incurred illness. In 2015, 2.8 million new episodes of RSV-related infec-
tions were reported in children <5 years of age in high income countries [1]. Of 
these, at least 383,000 cases required hospital admissions with 3300 accompanying 
deaths [1]. These figures represent a major healthcare burden, with costs estimated 
to be $545 million in the United States alone in 2009 [2].
Preterm birth, those born <37 weeks’ gestational age (wGA), has been associ-
ated with an increased risk for severe RSV-related disease requiring hospitalization 
(RSVH) [3]. Possible explanations for the increased RSV infection rates in preterm 
infants are incomplete airway development with reduced alveolar and bronchiolar 
diameter, increased air space wall thickness, immature immunologic responses, 
and reduced levels of maternally transmitted, RSV-specific antibodies compared to 
infants born at term [4]. Globally, about 15 million infants per year are estimated to 
be born premature, nearly 10% of all births, and thus are at potentially increased 
risk for RSV infection [5, 6]. Furthermore, the World Health Organization (WHO) 
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reported that the incidence of premature birth is rising [5]. This highlights the 
importance of preventing RSV-related LRTI and indeed, the WHO has declared the 
prevention of RSV to be a key healthcare priority [7]. Although several vaccines 
and antibodies are currently in preclinical or clinical development, it is likely to be 
several more years before any become commercially available [8, 9]. Therefore, cur-
rent therapeutic prevention relies solely on palivizumab, a humanized monoclonal 
antibody, which is indicated for the prevention of RSVH in high-risk infants, such 
as preterm infants born at ≤35 wGA or those with bronchopulmonary dysplasia 
(BPD)/chronic lung disease (CLD) or congenital heart disease (CHD) [10, 11]. 
However, several current guidelines, most notably from the American Academy 
of Pediatrics (AAP) and the Canadian Pediatric Society, seek to rationalize its use 
by recommending palivizumab only for infants born at <29 wGA without CLD 
[12–15], leaving the majority of preterm infants without therapeutic protection.
Risk-scoring tools (RSTs), models to estimate the risk of RSVH based on pre-
determined risk factors, have been developed to help identify infants at highest risk 
for RSVH, which may allow for targeted and cost-effective prophylaxis of infants 
born late preterm [16–19]. Some guidelines, such as those from Spain [20], Italy [21] 
and Austria [22], advocate the use of such a risk factor-based approach to extend 
prophylaxis to those preterm infants ≥30 wGA at highest risk.
This chapter aims to provide a rationale for palivizumab prophylaxis in late pre-
term infants and show that this can be cost effective with the use of validated RSTs.
2. Literature search
A literature review was undertaken using PubMed, EMBASE, and the Cochrane 
Library of studies including <37 wGA infants without CLD or CHD but with 
confirmed or probable RSV infection, published between 01 January 1998 and 31 
December 2018. To maximize comparability of data, only studies conducted in 
Western countries, defined as the US, Canada, and Europe (including Turkey and 
the Russian Federation) were included. The following search terms were used, com-
bined with Medical Subject Headings (MeSH): [“RSV” OR “respiratory syncytial 
virus” OR “lower respiratory tract infection” OR “LRTI” OR “acute respiratory tract 
infection” OR “ARTI” OR “ARI” OR “lower respiratory infection (LRI)” OR “bron-
chiolitis”] AND [“preterm” OR “premature” OR “gestational age” OR “gestation”] 
AND [“hospitalization*] OR [predisposition” OR “risk factor”] OR [“palivizumab” 
OR “Synagis” OR “immunoprophylax*” OR “prophylax*”] OR [“cost effective*” OR 
“Cost”] AND limits: “human, child (birth to 18 years)”. Additional publications and 
reference citations of potential relevance were included as identified by the authors. 
All original studies, systematic reviews, meta-analyses, and prophylaxis guidelines 
with at least an English abstract were reviewed.
As this chapter was based solely on published data, ethical approval was  
not required.
3. Results and discussion
3.1 Literature search
A total of 3532 publications were identified from the literature search, of which 
136 were deemed relevant (Figure 1). Another 20 references were identified from 
other sources, resulting in a final number of 156 publications considered during the 
drafting of this chapter.
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3.2 What do current guidelines recommend?
There is considerable variation in the published recommendations from national 
guidelines on the use of palivizumab prophylaxis in preterm infants. The AAP 2014 
policy [13, 14], which was unchanged following a review of new evidence in 2017 
[15], recommends prophylaxis for healthy preterm infants only if born ≤29 weeks 
and 0 days (29o wGA) and aged <1 year at the start of the RSV season. The justifica-
tion for this recommendation was partly based on a prospective, population-based 
surveillance program (n = 2149), undertaken from 2000 to 2005 in the US, which 
concluded that RSVH rates did not significantly differ between term (≥37 wGA) 
and preterm (<37 wGA) infants (5.3 vs. 4.6 per 1000 infants, respectively) [23]. 
Infants born at <30 wGA, on the other hand, experienced a significantly higher 
RSVH rate of 18.7 per 1000 infants [23]. Further evidence cited was from an 
analysis of the Tennessee Medicaid database (n = 248,652 infant-years), conducted 
in the 1990s, which reported higher rates of RSVH in infants <29 wGA compared to 
term infants with no underlying medical condition [24]. This difference remained 
consistently higher at up to 23 months of age: 0–5 months, 93.8 vs. 44.1 per 1000 
infants; 6–11 months, 46.1 vs. 15.0 per 1000 infants; and, 12–23 months, 30.0 vs. 
3.7 per 1000 infants [24]. Another study, which included 1029 ≤ 32 wGA preterm 
infants, found a decreasing RSVH incidence with increasing GA: ≤26 wGA, 139 per 
1000 infants; 27–28 wGA, 99 per 1000 infants; 29–30 wGA, 75 per 1000 infants; 
and 30–32 wGA, 44 per 1000 infants [25]. Predicated on this evidence, the AAP 
concluded that the risk of RSVH is considerably higher in those born ≤29° wGA 
compared to those born between 291 and 356 wGA and, therefore, prophylaxis 
should be recommended only in the former [13, 14]. A similar recommendation and 
rationale is presented in the Canadian RSV position statement, published in 2015 
[12]. The Canadian guideline concludes that it is “reasonable but not essential” to 
offer prophylaxis to infants born <30 wGA who are younger than 6 months at the 
start of the RSV season, but those born later do not merit prophylaxis, as the magni-
tude of difference in RSVH incidence between moderate to late preterm infants and 
infants born at term is not great enough to justify prophylaxis in this group [12]. The 
authors add that preterm infants are also less vulnerable to RSV infection nowadays 
Figure 1. 
PRISMA diagram: RSVH in preterm infants (<37 wGA) who received palivizumab.
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due to advances in technology and increased awareness of infection transmission. 
Preterm infants born >30 wGA are only eligible for prophylaxis if they live in 
remote regions and would require air transportation for hospitalization [12].
Other guidelines recommend more liberal use of prophylaxis for preterms, with 
Israeli guidelines, for example, recommending palivizumab for all preterm infants 
<33 wGA who are aged ≤1 year at the start of the RSV season and 33–35 wGA who 
are ≤6 months [26]. The Spanish and Italian guidelines recommend prophylaxis for 
those born between 29 and 31 wGA and aged ≤6 months at the start of the RSV sea-
son or if discharged during the season [20, 21]. For 32–35 wGA infants ≤6 months 
at the start of the RSV season, risk factors predisposing to severe infection and/or 
need for hospitalization guide the use of prophylaxis [20, 21]. Similar recommenda-
tions are reported in a recently published international, expert consensus guideline 
that guides cost-effective use of prophylaxis for high-risk 32–35 wGA infants with 
a validated RST [27]. Austrian guidelines have also adopted risk factors to guide 
prophylaxis for all 29–35 wGA infants, but with a chronological age cut-off of 
<6 months for 29–32 wGA and <3 months for 33–35 wGA [22].
3.3 Are late preterm infants at increased risk of RSVH compared to term infants?
Many studies in the literature report higher RSVH rates in late preterm infants 
and children (32–36 wGA) compared to those born at term (Table 1) [23, 28–31]. In 
a Dutch, community-based, cohort study that included 2099 children born between 
2002 and 2003 (62 with RSVH), otherwise healthy 32–36 wGA children had a three-
fold higher RSVH rate compared with full term children (3.9 vs. 1.2%, respectively; 
relative rate 3.2) [28]. Further evidence comes from a US, retrospective, cohort 
study involving 599,535 children (7597 admitted for RSVH) that reported a higher 
RSVH incidence in 33–36 wGA children compared to full term children (12.1 vs. 
7.8 per 1000 person-years) [29]. The adjusted hazard ratio for RSVH was 2.45 and 
1.92 for children born at 33–34 wGA and 34–36 wGA, respectively [29]. Another US 
Study Number Age 
(mo)
EP* LP* FT* 
(≥37 
wGA)
Prophy-
laxed
EP/LP 
definition 
(wGA)
Hall 2013 [23] 2149 <24 18.7 6.9 5.3 20% EP: <30  
LP: 32–34
Boyce 2000 
[24]
248,652 
infant-years
<6 81.8 79.8 44.1 NR EP: 29–32  
LP: 33–35
Stevens 2000 
[25]
1029 <12 230 119 NR NR EP: <29  
MLP: 29–32
Gijtenbeek 
2015 [28]
2099 <49 32 39 12 EP: 56.5% 
MP: 2.2%
EP: <32  
LP: 32–36
Helfrich 2015 
[29]
599,535 <24 NR 12.1+ 7.8+ 0% LP: 33–36
Haerskjold 
2015 [30]
421,943 <24 50.8+ 28.0+ 14.1+ NR EP: 23–32  
LP: 33–35
Cilla 2006 [31] 357 <12 44.2 78.1 1.91 0% EP: <33  
LP: 33–35
*Cases per 1000 infants; +cases per 1000 infant-years; RSVH, respiratory syncytial virus-related hospitalization; EP, 
early preterm; FT, full term; mo, months; LP, late preterm; MLP, moderate to late preterm; NR, not reported.
Table 1. 
Rates of RSVH.
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study, which included 247,566 infants (5322 RSVHs), found that 32–34 wGA infants 
were at double the risk of RSVH compared to term infants of the same age (odds 
ratio [OR] 1.94–2.41), and that the risk was highest in the youngest infants [32]. 
Young age was also associated with an increased risk of RSVH in 32–35 wGA infants 
in the REPORT study (n = 1642) [33]. Interestingly, older age was associated with 
higher rates of outpatient RSV visits, perhaps related to disease exposure [33]. A 
Danish database analysis found that, while RSVH incidence decreased with increas-
ing GA, 33–35 wGA children still had a RSVH rate twice as high as full term children 
(28.0 vs. 14.1 per 1000 years at risk) [30]. Another retrospective study, from Spain, 
investigating infants born between 1996 and 2000 (n = 357), reported a RSVH 
rate of 44.2 per 1000 children for <33 wGA infants compared to 1.91 per 1000 for 
≥38 wGA infants [31]. In this study, 33–35 wGA infants had the highest RSVH rate 
at 78.1 per 1000 [31].
Other studies have reported that there is not necessarily a simple linear rela-
tionship between lower GA and increased risk of RSVH. For example, in a large 
American database analysis involving 3,347,020 infants, RSVH rates were similar 
across all gestational age groups from <29 to 36 wGA (Figure 2) [34]. In 2016, a 
systematic review summarizing the evidence from 85 studies undertaken between 
1995 and 2015 concluded that, due to considerable variability in methodologies 
and results, it could not be clearly determined that infants born at younger GAs 
had higher RSVH rates [3]. Overall, reported RSVH rates were approximately three 
times higher in premature than term infants, although there was considerable vari-
ability across studies (range 1.1–8.1 times higher) [3].
Of potential note, two of the key studies cited by the AAP as evidence to restrict 
prophylaxis to ≤29° wGA infants reported moderate to late preterm infants to be 
at high risk of RSVH when considering those aged <6 months [23, 24]. In the US 
population-based surveillance program [23], the RSVH rate for 32–34 wGA infants 
≤5 months of age was 11.0 per 1000 children, compared to a rate of 2.6 per 1000 for 
those aged 6–23 months. Perhaps more revealing, the Tennessee Medicaid data-
base analysis [24] reported a RSVH rate of 79.8 per 1000 children for 33–35 wGA 
infants <6 months old compared to 44.1 per 1000 for age-matched, low-risk infants 
(incidence rate ratio: 1.8, 95% confidence interval [CI]: 1.5–2.1).
Figure 2. 
Rates of RSVH by gestational age group [34]. Hospitalization rates of infants aged less than 1 year at the time 
of first RSVH in a large American database analysis involving 1,683,188 infants insured via Medicaid and 
1,663,832 commercially insured infants [34]. RSVH, respiratory syncytial virus-related hospitalization; wGA, 
weeks’ gestational age.
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3.4 What are the consequences of RSVH in late preterm infants?
The health burden associated with RSVH in late preterm infants has been 
shown to be substantial [28, 35–38]. A pooled analysis of 7 prospective studies 
from across the Northern Hemisphere, involving 7820 infants born 33–35 wGA 
[39–45], reported a median length of stay (LOS) in hospital for RSV of 5.7 days, 
with 22.2% of infants requiring intensive care unit (ICU) admission for a 
median of 8.3 days [35]. Supplemental oxygen support was required by 70.4% 
of cases for a median of 4.9 days and 12.7% required mechanical ventilation for 
a median of 4.8 days [35]. The US SENTINEL1 study (n = 709) reported a mean 
RSVH LOS of 5 days with 42% of 29–35 wGA infants being admitted to the 
ICU (mean ICU LOS: 6 days) [36]. Of those admitted to the ICU, 19% required 
mechanical ventilation [46]. In a Dutch cohort study [28], the RSV disease bur-
den was found to be similar between <32, 32–36 and 38–42 wGA infants, with 
no significant differences in terms of hospital LOS (median of 8 vs. 7 vs. 7 days, 
respectively; p > 0.3), oxygen use (82.4 vs. 60.5 vs. 85.7%; p > 0.1), mechanical 
ventilation (5.9 vs. 15.8 vs. 42.9%; p > 0.1), or gavage feeding (29.4 vs. 39.5 vs. 
42.9%; p > 0.6). Other studies, however, have indicated that the disease burden 
in late preterm infants is higher than in term infants [37, 38]. In a European 
survey of 3474 infants hospitalized with LRTI [37], while overall LOS in hospital 
was similar for 33–36 wGA and term infants (mean 11 vs. 9 days, respectively), 
33.8% of the former were admitted to the ICU compared to only 14.1% of the 
latter. The highest disease burden was found in <29 wGA infants (mean LOS 
29 days; 54.3% ICU) followed by 29–32 wGA infants (mean 24 days; 48.8% ICU) 
[37]. A retrospective US study [38], involving 215 term infants and 89 infants 
<37 wGA, reported that 33–35 wGA infants had the highest rate of intubation 
(38.7 vs. ≤32 wGA: 21.4% vs. 36 wGA: 20.0 vs. ≥37 wGA: 12.1%; p = 0.002) and 
longest hospital LOS (mean 8.4 vs. 6.8 vs. 4.9 vs. 4.1 days; p < 0.0001) and ICU 
LOS (mean 7.7 vs. 5.8 vs. 4.2 vs. 3.8 days; p = 0.021) compared with infants in 
other GA groups.
As a consequence of RSVH, preterm infants may develop longer-term morbidi-
ties, such as recurrent wheezing [47–51]. In the SPRING study, a multicenter, 
observational, nested, case–control study undertaken in Spain, 32–35 wGA infants 
with RSVH (n = 125) had a significantly higher incidence of recurrent wheez-
ing through the first 6 years of life, independent of familial or childhood atopy, 
compared to infants born at the same GA without RSVH (n = 362) (66.7 vs. 49.2%, 
respectively; p = 0.001) [47]. While current wheezing rates remained higher 
in cases than controls each year, the difference remained significant only until 
3 years old. Allied to this, respiratory-related quality of life was significantly lower 
in RSVH cases than controls (TAPQOL: 93.96 vs. 95.76, respectively; p = 0.001). 
Hospital resource use through 6 years of life was also higher in RSVH cases than 
controls (outpatient services: 84.0 vs. 66.3%, respectively, p < 0.001; emergency 
care: 62.4 vs. 33.7%, p < 0.001). Further analysis revealed that RSVH was the single 
most important factor for recurrent wheezing (OR: 4.40; p < 0.001) [47]. Similar 
results have been reported in the Dutch RISK study [51]. At the 6-year follow-up of 
this birth cohort of 2210 32–35 wGA infants, the current wheezing rate was 27.7% 
for RSVH cases and 17.6% for non-hospitalized infants (OR: 1.8; 95% CI: 1.11–2.85). 
RSVH was found to be an independent risk factor for current wheezing at 6 years 
in children without atopic predisposition (OR: 4.1; 95% CI: 1.22–12.52) [51]. Other 
studies have reported higher healthcare resource utilization (including emergency 
department visits, outpatient visits, and hospitalizations) in late preterm infants 
in the year following RSV LRTI compared to their counterparts without such an 
infection [52, 53].
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3.5 How effective is palivizumab prophylaxis in late preterm infants?
Palivizumab has proven effective in late preterm infants, reducing the incidence 
of RSVH by up to 82% in prospective, comparative studies (Table 2) [8, 10, 11, 
39, 54]. A post-hoc analysis of the pivotal IMpact study, a randomized clinical trial 
including 724 preterm infants, showed the effectiveness of palivizumab to be 
similar in <29 wGA and 32–35 wGA infants (relative risk reduction: 80.4 vs. 82.1%, 
respectively) [11]. The Spanish FLIP-2 study, which reported a 68.3% reduction in 
RSVH with prophylaxis, found that not receiving palivizumab was an independent 
risk factor for RSVH (OR: 0.25; 95% CI: 0.13–0.49) in 32–35 wGA infants [39]. 
Registry data have confirmed the efficacy of palivizumab, with the Palivizumab 
Outcomes Registry from the US reporting RSVH rates of 0.2–1.6% in 32–35 wGA 
infants across four RSV seasons (2000–2004) [55], compared to 10.1% in the pla-
cebo arm of the IMpact trial [11]. Similar results were seen in the Canadian Registry 
of Palivizumab (CARESS) [56], with a RSVH incidence of 1.4% in 33–35 wGA 
infants during the 2006–2011 RSV seasons, compared to 8.2% (untreated subjects) 
in the IMpact study [11]. A propensity score weighted regression analysis based on 
a prospective, international trial (n = 849), showed that palivizumab prophylaxis 
significantly reduced RSVHs by 74.1% in 29–35 wGA infants, without comorbidi-
ties, aged ≤6 months [57].
Some studies have indicated that restricting palivizumab to ≤29 wGA infants 
does not increase the overall RSVH rate in children <2 years, while saving money on 
palivizumab prescriptions [58, 59]. A retrospective US study reported no differ-
ence in RSVH rates following introduction of the AAP 2014 policy (pre: 5.37/1000 
vs. post: 5.78/1000; p = 0.622) [58]. Similar results were reported in Italy follow-
ing introduction of the same policy in 2016, with the RSVH rate being 6.3/1000 
before implementation and 5.5/1000 afterwards [59]. Other studies, however, have 
reported RSVH rates to have increased by up to 103% following implementation of 
a more restrictive policy [60–63].
Several studies have indicated that, by preventing RSV infection, palivizumab 
can reduce subsequent wheezing in premature children, including those born late 
preterm [48, 54, 64–66]. In the MAKI study, a randomized, placebo-controlled trial 
of palivizumab that included 429 infants born at 32–35 wGA, the proportion of 
children with wheezing was reduced by 41.9% in the palivizumab group at 6 years 
(11.6 vs. 19.9% for placebo) [48]. Similar results were seen in the Japanese CREW 
study (n = 444; 349 received palivizumab ≤1 year), where recurrent wheezing was 
significantly lower in palivizumab-treated, 33–35 wGA infants than chronologically 
age-matched untreated infants (15.3 vs. 31.6%, respectively; p = 0.003) [65].
Study Number Gestational 
age group
RSVH incidence RRR 
(%)
Palivizumab Untreated
Notario 2014 [11] 724 32–35 wGA 1.8% 10.1% 82.1%
33–35 wGA 2.2% 8.2% 73.2%
MAKI study, Blanken 2013 [54] 429 33–35 wGA 0.9% 5.1% 82.4%
FLIP-2 study, Figueras-Aloy 2008 
[39]
5441 32–35 wGA 1.3% 4.1% 68.3%
RRR: relative risk reduction; RSVH: Respiratory-syncytial-virus-related hospitalization; wGA: weeks’ gestational age.
Table 2. 
Prospective, comparative studies on the effectiveness of palivizumab prophylaxis in reducing RSVH in late 
preterm infants.
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3.6 Can the use of risk factors target infants at highest risk for RSV infection and 
improve the cost-effectiveness of prophylaxis in the late preterm population?
A key argument for restricting the use of palivizumab to <29 wGA infants is 
cost-effectiveness. Late preterm infants represent approximately 85% of preterm 
births [6], and it is unrealistic that prophylaxis of all these infants would ever be 
cost-effective. For this reason, the use of risk factors, to identify infants at the 
highest risk of RSVH, appears a pragmatic approach. There have been several 
RSTs developed and validated, including those in Canada [17], Spain [18], and the 
Netherlands [41]. Recently, a RST, involving 32–35 wGA infants, was published 
using pooled, individual patient data (n = 13,475) from six prospective, observa-
tional studies across the Northern Hemisphere [16], which included Canada [40], 
Italy [42], the Netherlands [41], Spain [39], the US [44], and a multinational cohort 
comprising subjects from Europe, the Middle East, North America, and Asia [45]. 
The RST was externally validated against a further study from Ireland (n = 1078) 
[43]. The RST includes three risk factors: birth 3 months before and 2 months 
after the RSV season start date; smokers in the household and/or smoking during 
pregnancy; and siblings (excluding multiples) and/or (planned) day-care (Figure 3)  
[16]. Predictive accuracy was demonstrated to be good, with an area under the 
receiver operating characteristic curve (AUROC) of 0.773, and sensitivity/specific-
ity of 68.9 and 73.0%, respectively. The RST provides cut-off scores for infants 
at low- (≤19; 1.0% RSVH rate), moderate- (20–45; 3.3%), and high-risk (50–56; 
9.5%) for RSVH [16].
The cost-effectiveness of using the multinational RST has not been formally 
assessed; however, economic evaluations have been undertaken on the use of other 
RSTs or risk-factor based approaches to targeting prophylaxis in late preterm 
33–35 wGA infants [19, 67, 68]. The Canadian RST, based on data from the PICNIC 
study [40], included seven variables: small for GA (<10th percentile); male sex; born 
early during the RSV season (November, December, January); family history with-
out eczema; subject or siblings in daycare; >5 individuals in the home, including the 
subject; and, >1 smoker in the household [17]. The AUROC was 0.762 and sensitivity 
and specificity were 68.2 and 71.9%, respectively. The RST included cut-off scores 
of 0–48, 49–64, and 65–100 for low-, moderate-, and high-risk infants, respectively 
Figure 3. 
Risk factor scoring tool for late preterm infants [16]. 0 = No/Not Present; 1 = Yes/Present for one risk factor; 
2 = Yes/Present for both risk factors. Score—Low-risk: ≤19; Moderate-risk: 20–45; High-risk: 50–56.
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[17]. A cost-effective analysis from 2008, using a decision analytic model, reported 
incremental cost-effectiveness ratios (ICERs) of CDN$179,699, CDN$34,215, and 
CDN$5765 per quality-adjusted life year (QALY) for low-, moderate-, and high-risk 
infants, respectively; the ICERs for moderate- and high-risk infants were consid-
ered cost-effective under the Canadian healthcare system (medications commonly 
adopted with ICERs per QALY of CDN$50–75,000 at that time) [19]. The Dutch RST 
was based on data from the RISK study and included four variables: family atopy; 
birth Aug-14 to Dec-01; breastfeeding; and siblings or daycare attendance [41]. 
The AUROC was 0.703 and the cut-off score for low-risk was defined as <16 (3.5% 
RSVH rate) and for high-risk as ≥16 (10.0% RSVH rate) [41]. Assuming all high-risk 
infants would receive prophylaxis, a decision model analysis produced an ICER of 
€214,748 per QALY, for moderately preterm infants 32–35 wGA, which was consid-
ered not cost-effective at a threshold of €80,000 per QALY [67]. Another analysis on 
33–35 wGA infants, using data from the Spanish FLIP-2 study [39], assessed cost-
effectiveness based on infants having either 2 major risk factors and 2 minor risk 
factors (group A), 2 major and 1 minor risk factors (B), or 2 major risk factors (C) 
[68]. Major risk factors included chronological age < 10 weeks at the start of the RSV 
season or being born during the first 10 weeks of the season, school-age siblings or 
daycare attendance; whereas minor risk factors included maternal smoking during 
pregnancy and male sex [69]. Again using a decision analytic model, the incremental 
cost-utility ratio of €11,550.37, €14,177.18 and €13,937.61 per QALY gained for groups 
A, B and C, respectively, were derived and were deemed all highly cost-effective 
based on a threshold of €30,000 per QALY from both a National Health System and 
societal perspective [68]. An Austrian analysis reported palivizumab prophylaxis 
to be cost-effective in 33–35 wGA infants at €21,862 per QALY from the healthcare 
system perspective, when administered to those <3 months of age with risk fac-
tors [70]. It is important to note that the Canadian, Spanish and Austrian analyses 
modeled the effects of long-term respiratory morbidity, using life-time (Canadian 
and Austrian) and 6-year time horizons (Spanish), while the Dutch study included 
follow-up to only 1 year of age [19, 67, 68, 70]. This could, in part, account for the 
differences in cost-effectiveness reported. It would be interesting to see the impact 
on the ICERs if the increased rates of wheezing in children with a history of RSVH 
at 6 years in the RISK study (27.7 vs. 17.6% for non-hospitalized) were incorporated 
into the Dutch cost-effectiveness analysis. The ICERs reported from all three studies 
reflect costs from the healthcare system or payer perspective; including the societal 
impact of RSVH could potentially reduce the ICERs by 15–40% [19, 68]. The models 
also do not include the impact of RSV in the community setting, which could reduce 
the ICERs still further.
4. Conclusion
There is a sizable body of evidence demonstrating that late preterm infants 
are at increased risk of RSVH, resulting in substantial morbidity, both in terms 
of acute hospitalization and longer-term respiratory sequelae. While we await the 
availability of a safe and effective vaccine or a newer monoclonal antibody with an 
extended half-life, palivizumab remains the only proven therapy for reducing the 
incidence of RSVH in late preterm infants, and may also reduce subsequent wheez-
ing. The use of RSTs and risk factors provides a mechanism to cost-effectively 
target the most vulnerable of these infants to receive palivizumab. It is recom-
mended that countries adopt the multinational RST (Figure 3) and adapt this with 
local data and cut-offs, as available, to meet country-specific requirements and 
available funding.
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